Phenotypes Associated with This Genotype

Genotype
MGI:5007701

• Allelic Composition: Gt(ROSA)26Sor^{tm4(CAG-hsb5)Nki}/Gt(ROSA)26Sor⁺; Npm1^tm1Gsva/Npm1⁺; TgTn(pb-sb-GrOnc)#aGsva/0; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:172071 )

• mean survival of pIpC-treated mice is 99 days compared with 150 days for Gt(Rosa)26Sor^{tm4(CAG-hsb5)Nki} Gt(Rosa)26Sor⁺ Tg(Mx1-cre)1Cgn TgTn(pb-sb-GrOnc)#aGsva control mice

neoplasm

increased leukemia incidence ( J:172071 )

• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction

increased acute promyelocytic leukemia incidence ( J:172071 )

• in pIpC-treated mice

increased lymphoma incidence ( J:172071 )

• all mice develop aggressive leukemia and/or lymphoma within a year of pIpC induction

• however, pIpC-treated mice do not develop T cell lymphomas unlike in control mice

increased B cell derived lymphoma incidence ( J:172071 )

• in some pIpC-treated mice

increased hemangiosarcoma incidence ( J:172071 )

• angiosarcoma in some pIpC-treated mice